Biofrontera Inc. (NASDAQ:BFRI) Short Interest Down 50.2% in June

Biofrontera Inc. (NASDAQ:BFRI) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 27,890 shares, a decline of 50.2% from the June 15th total of 56,055 shares. Based on an average trading volume of 314,176 shares, the short-interest ratio is currently 0.1 days. Approximately 0.2% of the shares of the stock are short sold.

Hedge Funds Weigh In On Biofrontera

A hedge fund recently raised its position in Biofrontera stock. Rosalind Advisors Inc. increased its position in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the quarter. Biofrontera makes up 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th biggest position. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BFRI. Weiss Ratings upgraded Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Zacks Research downgraded shares of Biofrontera from a “hold” rating to a “strong sell” rating in a research note on Friday, July 3rd. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Biofrontera Price Performance

Shares of NASDAQ BFRI traded down $0.02 during trading on Friday, reaching $1.09. The company had a trading volume of 68,463 shares, compared to its average volume of 350,282. Biofrontera has a 52 week low of $0.55 and a 52 week high of $1.21. The business’s 50 day moving average price is $0.97 and its 200-day moving average price is $0.93. The stock has a market cap of $13.98 million, a PE ratio of -1.13 and a beta of 0.81. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.09 and a current ratio of 1.20.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.29). The company had revenue of $10.08 million for the quarter, compared to the consensus estimate of $10.25 million. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%. Analysts expect that Biofrontera will post -0.3 earnings per share for the current year.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.